Home > Insider Trading > Filing (0000899243-15-007464)

Filing Details

Accession Number:: 0000899243-15-007464
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-11-03 16:15:29
Reporting Period:: 2015-11-02

Filing Date:: 2015-11-03
Accepted Time:: 2015-11-03 16:15:29
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1466301	Clovis Oncology Inc.	CLVS	Pharmaceutical Preparations (2834)	900475355

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1051411	T Erle Mast	C/O Clovis Oncology, Inc. 2525 28Th Street, Suite 100 Boulder CO 80301	Executive Vp And Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2015-11-02	89	$98.82	138,494	No	4	S	Direct
Common Stock	Disposition	2015-11-02	111	$100.80	138,383	No	4	S	Direct
Common Stock	Disposition	2015-11-02	100	$102.67	138,283	No	4	S	Direct
Common Stock	Disposition	2015-11-02	500	$104.28	137,783	No	4	S	Direct
Common Stock	Disposition	2015-11-02	400	$105.10	137,383	No	4	S	Direct
Common Stock	Disposition	2015-11-02	1,000	$106.33	136,383	No	4	S	Direct
Common Stock	Disposition	2015-11-02	700	$107.29	135,683	No	4	S	Direct
Common Stock	Disposition	2015-11-02	100	$108.16	135,583	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

This transaction was executed in multiple trades at prices ranging from $100.00 to $100.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $103.75 to $104.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $104.83 to $105.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $105.86 to $106.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $106.96 to $107.77. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2014.